On August 11, Xunming Biotech announced the completion of Series B financing totaling 100 million US dollars. According to Xunming Biotechnology, this round of financing was completed in stages. Among them, the first round was exclusively invested by Granite Asia, the subsequent round was led by well-known industrial investors, followed by Honghui Fund, and existing shareholders such as Qiming Venture Capital, Jingwei Venture Capital, and Newley Capital continued to invest. So far, Xunming Biotech has raised nearly US$200 million. Xunming Biotech revealed that this round of financing will focus on the development and large-scale training of next-generation biobased models.

On August 11, Xunming Biotech announced the completion of Series B financing totaling 100 million US dollars. According to Xunming Biotechnology, this round of financing was completed in stages. Among them, the first round was exclusively invested by Granite Asia, the subsequent round was led by well-known industrial investors, followed by Honghui Fund, and existing shareholders such as Qiming Venture Capital, Jingwei Venture Capital, and Newley Capital continued to invest. So far, Xunming Biotech has raised nearly US$200 million. Xunming Biotech revealed that this round of financing will focus on the development and large-scale training of next-generation biobased models.